Ourofino - Results Center

4Q22 Earnings Release

Thu, 02 Mar 2023 17:50:00 GMT

1Q23

Thu, 02 Mar 2023 00:00:00 GMT

1Q23 Earnings Release

Largest veterinary pharmaceutical laboratory of Brazilian origin and 3rd largest in the general ranking of SINDAN
Certified for the 3rd consecutive year as one of the best companies to work for by GPTW
Leverage reduction to 0.9x EBITDA, with 78% of long-term debt, 76% of all gross debt via FINEP and BNDES and average annual cost of 10.3%
Robust operating cash generation of R$91 million, R$74 million more than the same period of the previous year

2Q23

Thu, 02 Mar 2023 00:00:00 GMT

2Q23 Earnings Release

Once more, we were recognized By GPTW as the 2nd best company to work for in agrobusiness, reinforcing our care for people.
For the third year we received the Agroleite trophy in the animal health category, an award considered the "Oscar of Milk
Operating cash generation of R$164.2 million, R$97.2 million more than the same period of the previous year
Leverage decline to 0.81x EBITDA, with 75.2% of long-term debt, 75% of all gross debt via FINEP and BNDES and average annual cost of 10.9%
2 new products launched for Companion Animals in the quarter.

3Q23

Thu, 02 Mar 2023 00:00:00 GMT

3Q23 Earnings Release:

Operating cash generation of R$202.3 million, R$146.4 million higher than the same period of the previous year.
Leverage decline to 0.5x EBITDA, with 71.4% of long-term debt, 83,7% of all gross debt via FINEP and BNDES and an average debt cost of 10.0% in 3Q23.
We moved up 15 positions in the ranking of the best 150 best companies to work for Brazil by GPTW, and we are also the 2nd best in the agribusiness sector.
3rd place among the companies that most pratice open innovation with startups in the country, in Agribusiness category, by Top 100 Open Corps.

4Q23

Thu, 02 Mar 2023 00:00:00 GMT

4Q23 Earnings Release:

Resumption of growth in Companion Animals, representing 10.7% compared to 4Q22.
Operating cash generation of R$ 190.3 million, R$ 100.7 million higher versus the previous year.
Leverage decline from 1.2x to 0.9x EBITDA, with 77.1% of debt in the long term, and an average annual cost of debt of 8.3% p.a.
We moved up 15 positions in the ranking of the best 150 best companies to work for Brazil by GPTW, and we are also the 2nd best in the agribusiness sector.

1Q24

Thu, 02 Mar 2023 00:00:00 GMT

1Q24 Earnings Release:

Net revenue grew 6.7% in 1Q24 to R$ 178.4 million
Growth in Production Animals, representing 12.7% compared to 1Q23.
Growth for the second quarter in a row in Companion Animals, representing 16.3% compared to the previous year.
Strong growth in profitability indicators: Gross margin +3.1 p.p., EBITDA margin +11.8 p.p. and Net margin +7.8 p.p.
Leverage Decline from 0.9x to 0.5x EBITDA, with 76.7% of debt in the long term, and an average annual cost of debt of 7.7% p.a.

2Q24

Thu, 02 Mar 2023 00:00:00 GMT

2Q24 Earnings Release:

Revenue ex-Food-and-Mouth grows 7.3% in 2Q24 and 7.0% in the six-month period.
Growth in Production Animals, representing 10.7% compared to 2Q23 (ex-Foot-and-Mouth).
Strong growth in Companion Animals, representing 16.3% compared to the previous year.
Growth in profitability indicators: Gross margin +2.3 p.p., EBITDA margin +5.0 p.p. and Net margin +5.0 p.p. in the six-month period.
Leverage decline from 0.9x to 0.4x EBITDA, with 76.5% of debt in the long term, and an average annual cost of debt of 7.9% p.a. at the end of the period.
Robust operating cash generation, reaching R$ 100 million in 6M24.

3Q24

Thu, 02 Mar 2023 00:00:00 GMT

3Q24 Earnings Release:

Net Revenue recorded 11.2% growth in 3Q24, with accumulated growth in 9M24 of 8.5%, reaching R$671.1 million
Growth in Production Animals, representing 8.9% compared to 9M23
Strong growth in Companion Animals, representing 25.9% in 3Q24 and 19.6% in 9M24 compared to the previous year.
Strong growth in profitability indicators: Gross margin +5.3 p.p., EBITDA margin +8.5 p.p. and Net margin +10.3 p.p. compared to the previous year.
Adjusted EBITDA reaches R$ 139.9 million with 82.1% growth.
Maintaining leverage levels at 0.6x EBITDA, with 85% debt in the long term, and an average annual cost of debt of 7.5% p.a.

4Q24

Thu, 02 Mar 2023 00:00:00 GMT

4Q24 Earnings Release:

Net revenue (ex. foot-and-mouth disease) grew 26.1% in 4Q24 and 14.1% in the accumulated 12M24, reaching R$ 1,017.8 million
Growth in Production Animals (ex. foot-and-mouth disease), representing 14.7% compared to 12M23 and 27.8% compared to 4Q23.
Growth in Companion Animals, representing 9.2% in 4Q24 and 16.5% in 12M24 compared to the previous year.
Strong growth in profitability indicators: Gross margin +7.5 p.p., Adjusted EBITDA Margin +7.4 p.p. and Net margin +7.3 p.p. compared to the previous year.
Adjusted EBITDA reaches R$ 221.7 million with 65.0% growth.
Leverage at 0.6x EBITDA, with 83.7% of the debt in the long term and an average cost of 7.93% per year at the end of the period

1Q25

Thu, 02 Mar 2023 00:00:00 GMT

1Q25 Earnings Release:

Net revenue grew 6.3% in 1Q25, reaching R$ 189.6 million ?
Production Animals, net revenue of R$ 125.5 million, in line with the results of 1Q24
Growth in Companion Animals, representing 7.9% no 1Q25, reaching R$ 36.6 million
Strong Growth in International Operations, representing 45.1% in 1Q25, and a net revenue of R$ 27.5 million
Growth in gross margin + 0,5 bps.
Adjusted EBITDA of R$ 18.7 million
Leverage at 0.9x EBITDA, with 84,6% of the debt in the long term and an average cost of 8,42% year to date.

2Q25

Thu, 02 Mar 2023 00:00:00 GMT

2Q25 Earnings Release:

Net revenue grew 19.3% in 2Q25 and 13.4% in the first 6 months of 2025.
Robust Growth in Production Animals, with net revenue reaching R$ 196.8 million, 27.8% growth compared to 2Q24.
Growth in International Operations, representing 19.4% in 6M25 with net revenue of R$ 55.5 million.
Consolidated gross margin growth of +0.5 p.p. in 6M25.
Adjusted EBITDA in the quarter of R$ 49.8 million, growing 26.5% compared to 2Q24.
Leverage at 1.1x EBITDA, with 87.2% of debt in the long term and an average cost at the end of the period of 8.20% p.a.

3Q25

Thu, 02 Mar 2023 00:00:00 GMT

3Q25 Earnings Release:

Net revenue grew 26.2% in 3Q25, and 18.7% in the first 9 months of 2025.

Production Animals, net revenue of R$ 272.2 million, 29.1% growth compared to 3Q24.?

Companion Animals, net revenue of R$ 45.2 million, 9.8% growth compared to 3Q24.

International Operations, growth of 28.1% in 3Q25, and a net revenue of R$ 39.1 million
Growth in gross profit, 22.1% in 3Q25, reaching R$ 188.3 million
Adjusted EBITDA in the quarter of R$ 97.6 million, growing 30.6% compared to 3Q24.
Leverage at 1.16x EBITDA, with 89.4% of the debt in the long term and an average cost of 8,25% at the end of the period.

4Q25

Thu, 02 Mar 2023 00:00:00 GMT

4Q25 Earnings Release:

Consolidated net revenue reached R$ 1,225 million, 19.5% growth compared to 2024

In Production Animals, net revenue reached R$ 901.2 million, 21.9% growth compared to 2024.

In Companion Animals, net revenue reached R$ 172.4 million, 10.4% growth compared to 2024.

Net revenue from International Operations reached R$ 151.4 million. 17.1% increase compared to 2024.
Gross profit grew 22.3% in 2025, reaching R$ 633.0 million, + 1.2 p.p. of gross margin.
Adjusted EBITDA amounted to R$ 282.5 million, with 27.4% increase versus 2024. Adjusted Net Income grew 32.1% to R$ 172.4 million.
Leverage at 0.85x EBITDA, with 89.3% of debt in the long term and an average cost at the end of the period of 8.23% p.a.

4Q22

Thu, 02 Mar 2023 00:00:00 GMT

4Q22 Earnings Release

Net revenue exceeded the mark of R$ 1 billion with 15% growth as compared to 2021, amounting to R$ 1,041 million.
Year-to-date from 2019, net revenue and net income recorded 68% and 177% growth, respectively
EBITDA reaches R$ 207.2 million in 2022, with 20.1% growth compared to 2021.
Record operating cash generation, reaching R$ 152 million, 72% higher than the same period of the previous year.
Leverage Decrease to 1.18x EBITDA, with 79% of long term debt, 77% of debt via FINEP and BNDES and average annual cost of 10.3%

3Q22 Earnings Release

Thu, 10 Nov 2022 16:22:00 GMT

3Q22

Thu, 10 Nov 2022 00:00:00 GMT

3Q22 Earnings Release

Elected the most amazing pharmaceutical company to work for by FIA/USP and UOL
Net Revenue recorded 19.5% growth in 3Q22, raising the accumulated growth in 9M22 to 13.2%, reaching R$ 718.3 million
Gross margin reaches 52.3% in 3Q22 with 50.6% accumulated margin in 9M22, amounting to R$ 363.2 million in gross profit
EBITDA reaches R$ 137.5 million with 9.3% growth
Leverage at 1.3x EBITDA, with 75% of debt via FINEP and BNDES

2Q22

Thu, 04 Aug 2022 00:00:00 GMT

2Q22 Earnings Release

Net revenue grew 9.5% in 6M22 to R$ 437.6 million
Gross profit reaches R$ 216.4 million with 49.5% gross margin in 6M22
Leverage of 1.37x EBITDA, including debt cost at 9.9% per year and 80% of
the long-term debt.
Operating cash generation in 6 months reaches R$ 67 million, 53% higher than the same period in 2021

1Q22 Earnings Release

Thu, 12 May 2022 16:30:00 GMT

4Q21 Earnings Release

Thu, 24 Feb 2022 17:57:00 GMT

4Q21

Thu, 24 Feb 2022 00:00:00 GMT

4Q21 Earnings Release

Net revenue grows 24% and reaches R$ 905 million in 2021
Net income grows 32% in 2021 and reaches R$ 113 million, with 12% net margin
Year-to-date from 2019, net revenue and net income recorded 46% and 141% growth, respectively
Leverage at 1.28x EBITDA, cost of debt at 8% per year and 78% of long term debt

1Q22

Thu, 24 Feb 2022 00:00:00 GMT

1Q22 Earnings Release

Net revenue in 1Q22 grows 19.9% to R$ 202.3 million
Adjusted EBITDA reached R$ 28.9 million in 1Q22 (15.1% growth)
Adjusted net income of R$ 13.9 million in 1Q22
Leverage of 1.4x EBITDA, including debt cost at 9.2% per year and 78% of
the long-term debt.

3Q21 Earnings Release

Tue, 23 Nov 2021 17:35:00 GMT

2Q21 Earnings Release

Tue, 23 Nov 2021 17:32:00 GMT

1Q21 Earnings Release

Tue, 23 Nov 2021 17:31:00 GMT

4Q20 Earnings Release

Tue, 23 Nov 2021 17:28:00 GMT

3Q21

Thu, 11 Nov 2021 00:00:00 GMT

3Q21 Earnings Release

Net revenue and EBITDA grow 25% in 9M21 and reach R$ 635 million
and R$ 126 million, respectively
Net income grows 29% in 9M21 and reaches R$ 74 million
Operating cash generation at R$ 100 million in 9M21, with R$ 56
million in the quarter
Leverage at 0.8x EBITDA

2Q21

Thu, 05 Aug 2021 00:00:00 GMT

2Q21 Earnings Release

Company's consolidated net revenue grows 41% in 6M21, amounting to R$ 400 million
6M21 adjusted EBITDA grows 74% and reaches R$ 76 million
Operating cash generation at R$ 43.8 million
Net debt declines 10% and leverage is 0.97x Adjusted EBITDA

4Q20

Fri, 05 Mar 2021 00:00:00 GMT

4Q20 and 12M20 Results

Net revenue in 12M20 grows 18% to R$ 730 million;
12M20 adjusted EBITDA grows 33% and reaches R$ 142 million;
12M20 adjusted net income grows 83% to R$ 86 million;
Operating cash generation grows 57% and reaches R$ 136 million in 12M20;
Net debt declines 38% in 12M20 and leverage is 1.04x Adjusted EBITDA.

3Q20

Mon, 09 Nov 2020 00:00:00 GMT

Highlights:

Net revenue in 9M20 grows 20% to R$ 510 million
9M20 adjusted EBITDA grows 61% and reaches R$ 101 million
9M20 adjusted net income grows 162% to R$ 58 million
Operating cash generation at R$ 130 million in 9M20
Net debt declines 38% and leverage is 1.02x Adjusted EBITDA

2Q20

Thu, 06 Aug 2020 00:00:00 GMT

Resultados do 2T20

Receita líquida consolidada da Companhia cresce 6% nos 6M20 somando R$ 284 milhões;
Margem bruta dos 6M20 cresce 1 p.p. e alcança 50%;
Geração operacional de caixa de R$ 79 milhões nos 6M20;
Dívida líquida reduz 21% no semestre e alavancagem está em 1,6x EBITDA.

1Q20

Tue, 12 May 2020 00:00:00 GMT

1Q20 Earnings Release

Net revenue from the production animals segment increased by 20% in the quarter
Net revenue from the international operations segment increased by 66% in the quarter
Generation of cash from operations of R$ 42 million, with an improvement of 45 days in the financial cycle
Cash position strengthening through the raising of R$ 90 million

1Q21

Tue, 12 May 2020 00:00:00 GMT

1Q21 Earnings Release

Net revenue in 1Q21 grows 51% to R$ 169 million
1Q21 adjusted EBITDA grows 383% and reaches R$ 25 million
R$ 9.6 million adjusted net income in 1Q21
Operating cash generation at R$ 23.5 million in 1Q21
Net debt declines 30% and leverage is 0.9x Adjusted EBITDA

4Q19

Tue, 11 Feb 2020 00:00:00 GMT

4Q19 and 12M19 Results

Consolidated net revenue grows 5% and reaches R$ 620 million in 2019;
Net revenue from companion animals grows 17% and reaches R$ 88 million in the year;
Net revenue from international operations increases 17% and totals R$ 64 million in the year;
Consolidated 4th quarter net revenues grows 12% reaching R$ 197 million with EBITDA of R$ 45 million, margin of 23%, 22% of growth.

3Q19

Tue, 05 Nov 2019 00:00:00 GMT

3Q19 and 9M19 Results

A new strategic planning cycle has begun to ensure business sustainability;
Protein market has maintained positive prospects;
Revenues from the companion animals segment increased by 11% and reached R$ 20 million in the quarter;
Generation of cash from operations in 9M19 reached R$ 81 million, 53% over 9M18.

2Q19

Wed, 07 Aug 2019 00:00:00 GMT

2Q19 Earnings Release

The Company’s revenues increased by 10% in the quarter;
Revenues from the companion animals segment increased by 22% and reached R$ 24 million, the highest historical quarterly revenue for the segment;
Revenues from the production animals segment reached R$ 139 million in the quarter, the highest historical quarterly revenue for the segment;
Generation of cash from operations in 2Q19 totaled R$ 26 million, that is, six times over 2Q18.

1Q19

Tue, 07 May 2019 00:00:00 GMT

1Q19 Earnings Release

The Brazilian Association of Animal Health Product Manufacturers (Sindan) has released its rankings for 2018 - Ourofino has regained the third position
Local rankings in Mexico and Colombia show that Ourofino ranked second in terms of growth in those countries in 2018
Revenue from international operations increased by 48% in 1Q19, of which 36% in local currency
The generation of cash from operations totaled R$ 41 million and net debt/EBITDA remained at 1.7x

4Q18

Tue, 26 Feb 2019 00:00:00 GMT

4Q18 and FY2018 Earnings Release

Best year in net revenues for the Company and also increasing its profitability
Net revenue increased by 17% and reached R$ 589 million
Adjusted EBITDA for the year increased by 27% and reached R$ 132 million, with a margin of 22%
Adjusted profit increased by 56% in 2018 and totaled R$ 71 million, with a margin of 12%

3Q18

Tue, 06 Nov 2018 00:00:00 GMT

3Q18 Earnings Release

Strong increase in revenues and continuous profit improvement.
Net revenue increased by 23% in the quarter with a gross margin of 57%.
Adjusted EBITDA in the quarter increased by 41% with a margin of 26%.
Adjusted profit increased by 84% with a net margin of 15% in the quarter, that is, an increase of 5 p.p.
Adjusted cumulative EBITDA for the 12-month period totaled R$ 136 million, at one of the lowest historical leverage levels.

2Q18

Mon, 06 Aug 2018 00:00:00 GMT

2Q18 Earnings Release

Net revenue increased by 17% in the quarter and reached R$ 162 million
Adjusted EBITDA in the quarter increased by 26% and totaled R$ 41 million with an EBITDA margin of 25%
Accumulated EBITDA for the 12-month period totaled R$ 124 million
Gross margin increased by 1.4 p.p. and reached 53% in the quarter

1Q18

Tue, 08 May 2018 00:00:00 GMT

1Q18 Earnings Release

Net revenue increased by 22% and reached R$ 92 million
Gross margin increased by four percentage points and SG&A expenses diluted nine percentage points
EBITDA margin increased by 12 percentage points and profit reached R$ 4 million, thus reversing the loss for 1Q17
Generation of cash from operations of R$ 25 million and leverage of 1.7x net debt/EBITDA

2017 Annual Report (Portuguese only)

Mon, 09 Apr 2018 11:09:00 GMT

(Portuguese Only)

4Q17

Tue, 06 Mar 2018 00:00:00 GMT

4Q17 Earnings Release

Net revenue increased by 11% and reached R$ 505 million
Adjusted EBITDA increased by 134% and reached R$ 104 million, with an adjusted profit of R$ 45 million
Generation of cash from operations doubled and reached R$ 120 million
Leverage level (adjusted net debt/EBITDA) reaches 2x.

3Q17

Thu, 09 Nov 2017 00:00:00 GMT

3Q17 Earnings Release

Resuming historical profitability levels
Generation of cash from operations of R$ 95 million in accumulated figures for 2017

2Q17

Tue, 08 Aug 2017 00:00:00 GMT

2Q17 Earnings Release

Resuming historical profitability levels in the quarter;
EBITDA margin of 23.2%;
Net margin of 10.8%.

1Q17

Tue, 09 May 2017 00:00:00 GMT

1Q17 Earnings Release

Generation of cash from operations of R$ 44.7 million, thus reducing net debt by 10.2%;
Companion Animals increases its net revenue by 16.3% compared to 1Q16;
Increase of 5.9 p.p. in gross margin in comparison with the 2nd half of 2016.

4Q16

Tue, 21 Mar 2017 00:00:00 GMT

4Q16 and FY2016 Earnings Release

The year was marked by significant market challenges, the return of one of the founding partners as CEO, and path adjustments to resume the historical levels of performance;
The quarter was impacted by the sales rationalization process, with adjustments to sales conditions, seeking to lay more solid groundwork for 2017, which caused a significant and expected reduction in volumes.

3Q16

Mon, 14 Nov 2016 18:00:00 GMT

Earnings Release 3T16

A challenging year due to a combination of economic and market factors
Jardel Massari, co-founder and controlling stockholder, reassumes the CEO role
Two products were launched in the quarter, totaling 6 launches in the year

2Q16

Tue, 09 Aug 2016 00:00:00 GMT

Earnings Release 2T16

Net revenue increased by 5.9% in 1H16 totaling R$ 232.6 million against R$ 219.7 million in 1H15
Four new products were launched in 1H16

1Q16

Mon, 16 May 2016 00:00:00 GMT

Earnings Release 1Q16

Net revenue increased by 12.6% in 1Q16, totaling R$ 98 million against R$ 87 million in 1Q15
Launch of 2 new products in the quarter

4Q15

Mon, 16 May 2016 00:00:00 GMT

4Q15 and FY2015 Earnings Release

Net revenue increased by 23.6% in 2015, totaling R$ 534.0 million against R$ 432.2 million in 2014
EBITDA increased by 21.3% to R$ 119.1 million in 2015
Profit increased by 27.7%, totaling R$ 69.2 million in 2015
Nine new products were launched in the year

3Q15

Mon, 16 May 2016 00:00:00 GMT

3Q15 and 9M15 Earnings Release

Net revenue increased by 24.4% in 9M15 against 9M14 and totaled R$ 369.2 million
Profit increased by 33.9% and totaled R$ 45.4 million in 9M15
Seven new products were launched in 9M15

2Q15

Mon, 16 May 2016 00:00:00 GMT

2Q15 and 1H15 Earnings Release

Net revenue increased by 13.8% in 1H15 against 1H14 and reached R$ 219.7 million
Profit increased by 20.5% and totaled R$ 26.4 million in 1H15
Four new products were launched in 1H15

1Q15

Mon, 16 May 2016 00:00:00 GMT

Earnings Release 1Q15

As compared to 1Q14, in 1Q15 our net revenue increased by 16.0% and totaled R$ 87.0 million; our EBITDA increased by 13.8% and totaled R$ 14 million, and our profit increased by 33.9% and totaled R$ 7.5 million.

4Q14

Mon, 16 May 2016 00:00:00 GMT

4Q14 and FY2014 Earnings Release

Our net revenue increased by 12.6% and adjusted EBITDA reached R$ 98.2 million, a nominal increase of 15.4% and 0.5 percentage points in the margin on net revenue, evidencing the Company's capacity of generating value.

3Q14

Mon, 16 May 2016 00:00:00 GMT

3Q14 & 9M14 Earnings Release

The Company recorded revenue of R$103.7 million in 3Q14, versus R$94.3 million in 3Q13, up 10.0%, and R$296.8 million in 9M14, versus 247.2 million in 9M13, up 20.1%, which shows the Company’s solid position in the animal health market.

2Q14

Mon, 16 May 2016 00:00:00 GMT

(Portuguese Only)

1Q14

Mon, 16 May 2016 00:00:00 GMT

(Portuguese Only)

4Q13

Mon, 16 May 2016 00:00:00 GMT

(Portuguese Only)